Perioperative safety of thymectomy in myasthenia gravis patients with oral high-dose glucocorticoids
- VernacularTitle:口服大剂量激素的重症肌无力患者行胸腺切除术的围术期安全性分析
- Author:
Jinjin YAN
1
;
Dazhi PANG
1
;
Jitian ZHANG
1
;
Guangqiang SHAO
1
;
Zhihai LIU
1
;
Rutaiyang LIU
1
Author Information
1. Department of Thoracic Surgery, The University of Hong Kong-Shenzhen Hospital, Shenzhen, 518000, Guangdong, P. R. China
- Publication Type:Journal Article
- Keywords:
Myasthenia gravis;
glucocorticoids;
thymectomy;
safety;
complications;
perioperative management
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2026;33(04):565-569
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the perioperative safety of patients with myasthenia gravis who take high doses of oral glucocorticoids. Methods A retrospective analysis was conducted on the clinical data of patients with myasthenia gravis who received oral glucocorticoids and underwent thoracoscopic thymectomy at the Department of Thoracic Surgery, the University of Hong Kong-Shenzhen Hospital from April 2013 to October 2019. Patients were divided into a high-dose steroid group and a medium-to-low dose steroid group based on the dosage of oral steroids, and the clinical data of the two groups were compared. Results A total of 102 patients were included, including 19 (18.62%) males and 83 (81.37%) females, with an average age of (32.25±9.83) years. There were 75 patients in the medium-to-low dose steroid group and 27 patients in the high-dose steroid group. All patients in both groups successfully completed the surgery without major intraoperative bleeding, conversion to open chest surgery, delayed extubation, severe infection, or perioperative death. The daily oral steroid dose for the high-dose steroid group was (35.81±4.29) mg, and for the medium-to-low dose steroid group it was (15.29±2.17) mg. There was no statistical difference in the operation time [(124.69±23.51) min vs. (117.89±21.46) min, P=0.172] and intraoperative blood loss [(21.19±3.48) mL vs. (20.56±3.41) mL, P=0.419] between the two groups. Postoperatively, 12 (11.76%) patients developed complications: one patient of myasthenic crisis (the medium-to-low dose steroid group), which was improved after short-term respiratory support and intravenous immunoglobulin treatment; 11 patients of respiratory/swallowing difficulties (9 in the medium-to-low dose steroid group and 2 in the high-dose steroid group), which were improved after anticholinergic treatment to reduce oral secretions and sputum suction, and the patients were discharged smoothly. There was no statistical difference in the incidence of postoperative complications between the two groups (P=0.637). Conclusion On the basis of good perioperative management, it is safe and feasible for patients with myasthenia gravis who take high dose of oral steroids to undergo thymectomy, and they have the same perioperative safety as patients with medium-to-low dose steroids.
